---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-000832"
form_type: "8-K"
ticker: "IMCR"
cik: "0001671927"
company_name: "Immunocore Holdings plc"
filed_at: "2024-01-05T23:59:59+00:00"
generated_at: "2026-06-07T03:09:39.570758+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Immunocore strategic update: KIMMTRAK expansion, PRAME Phase 3 start, new autoimmune candidates

## Summary
- Preliminary cash and cash equivalents ~$443M as of Dec 31, 2023.
- KIMMTRAK expansion: TEBE-AM (2L+ cutaneous melanoma) Phase 2 data Q4 2024; ATOM (adjuvant uveal melanoma) Phase 3 start 2H 2024.
- PRAME franchise: PRISM-MEL-301 Phase 3 in 1L cutaneous melanoma to begin randomization Q1 2024; Phase 1/2 data across melanoma, ovarian, NSCLC expected in 2024.
- New candidates: IMC-R117C (PIWIL1) for GI cancers; two autoimmune candidates for type 1 diabetes and dermatology.
- HIV candidate IMC-M113V Phase 1 MAD data expected 2H 2024; HBV trial amended to include HCC.

## SEC filing metadata
- accession: 0001140361-24-000832
- form_type: 8-K
- ticker: IMCR
- cik: 0001671927
- company_name: Immunocore Holdings plc
- filed_at: 2024-01-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671927/000114036124000832/0001140361-24-000832-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671927/000114036124000832/ef20018111_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-000832
- JSON: https://secwatch.observer/filing/0001140361-24-000832.json
- Plain text: https://secwatch.observer/filing/0001140361-24-000832.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.